IDH1 and neoplasm: Endothelial growth factor receptor (EGFR), isocitrate dehydrogenase (IDH), tumor protein p53, loss of heterozygosity 10q, platelet-derived growth factor receptor alpha (PDGFRA), and circulating tumor cells acts as prognostic biomarkers where the concentration of these biomarkers act as disease progression or the success of therapy.